Results 11 to 20 of about 74,289 (208)

Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors

Molecules, 2021
Despite not being utilized as considerably as other antidepressants in the therapy of depression, the monoamine oxidase inhibitors (MAOIs) proceed to hold a place in neurodegeneration and to have a somewhat broad spectrum in respect of the treatment of ...
Tapan Behl, Felicia Cioara, Simona Bungau   +2 more
exaly   +3 more sources

Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders

Molecules, 2019
Monoamine oxidase inhibitions are considered as important targets for the treatment of depression, anxiety, and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases.
Eduardo Sobarzo-Sanchez, Eugenio Eu Uriarte, Anurag Khatkar   +2 more
exaly   +3 more sources

Structures and mechanism of the monoamine oxidase family

Biomolecular Concepts, 2011
Members of the monoamine oxidase family of flavoproteins catalyze the oxidation of primary and secondary amines, polyamines, amino acids, and methylated lysine side chains in proteins.
Paul F Fitzpatrick
exaly   +2 more sources

Molecular docking approach of monoamine oxidase B inhibitors for identifying new potential drugs: Insights into drug-protein interaction discovery [PDF]

Journal of Cell and Molecular Research, 2013
Monoamine oxidase (EC, 1.4.3.4) or amine oxidoreductase catalyzes the oxidative deamination of biogenic amines. Abnormal action of the monoamine oxidase B has been associated with neurological dysfunctions including parkinson´s disorder.
Salimeh Raeisi
doaj   +1 more source

Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease

eNeurologicalSci, 2020
Background: Dopamine replacement therapy is an established treatment for motor symptoms of Parkinson's disease, but its long-term use is often limited by the eventual development of motor complications, including levodopa-induced dyskinesia.
Shoko Kakinuma, Minako Beppu, Setsu Sawai, Akitoshi Nakayama, Shigeki Hirano, Yoshitaka Yamanaka, Tatsuya Yamamoto, Chigusa Masafumi, Xiamuxiya Aisihaer, Alimasi Aersilan, Yue Gao, Kenichi Sato, Itoga Sakae, Takayuki Ishige, Motoi Nishimura, Kazuyuki Matsushita, Mamoru Satoh, Fumio Nomura, Satoshi Kuwabara, Tomoaki Tanaka   +19 more
doaj   +1 more source

Synthesis and Biological Evaluation of O⁶-Aminoalkyl-Hispidol Analogs as Multifunctional Monoamine Oxidase-B Inhibitors towards Management of Neurodegenerative Diseases

Antioxidants, 2023
Oxidative catabolism of monoamine neurotransmitters by monoamine oxidases (MAOs) produces reactive oxygen species (ROS), which contributes to neuronal cells’ death and also lowers monoamine neurotransmitter levels.
Ahmed H. E. Hassan, Hyeon Jeong Kim, Keontae Park, Yeonwoo Choi, Suyeon Moon, Chae Hyeon Lee, Yeon Ju Kim, Soo Bin Cho, Min Sung Gee, Danbi Lee, Jong-Hyun Park, Jong Kil Lee, Jong Hoon Ryu, Ki Duk Park, Yong Sup Lee   +14 more
doaj   +1 more source

8-Propyl-6H-[1,3]dioxolo[4,5-g]chromen-6-one: A new coumarin with monoamine oxidase B inhibitory activity and possible anti-parkinsonian effects

Brazilian Journal of Pharmaceutical Sciences, 2020
Parkinson’s disease is a common neurodegenerative disorder. In this study, the monoamine oxidase inhibitory activity and potential anti-parkinsonian effects of 8-propyl-6H-[1,3]dioxolo[4,5-g]chromen-6-one (FCS303), a new synthetic coumarin, were ...
María del Pilar Olaya, Nadezdha Esperanza Vergel, Jose Luis López, Dolores Viña, Mario Francisco Guerrero   +4 more
doaj   +1 more source

Amphetamine Derivatives as Monoamine Oxidase Inhibitors

Frontiers in Pharmacology, 2020
Amphetamine and its derivatives exhibit a wide range of pharmacological activities, including psychostimulant, hallucinogenic, entactogenic, anorectic, or antidepressant effects.
Miguel Reyes-Parada, Miguel Reyes-Parada, Patricio Iturriaga-Vasquez, Bruce K. Cassels   +3 more
doaj   +1 more source

Pharmacological Modulation of Behaviour, Serotonin and Dopamine Levels in Daphnia magna Exposed to the Monoamine Oxidase Inhibitor Deprenyl

Toxics, 2021
This study assessed the effects of the monoamine oxidase (MAO) inhibitor deprenyl in Daphnia magna locomotor activity. The mechanisms of action of deprenyl were also determined by studying the relationship between behaviour, MAO activity and ...
Marina Bellot, Melissa Faria, Cristian Gómez-Canela, Demetrio Raldúa, Carlos Barata   +4 more
doaj   +1 more source

Monoamine oxidase inhibitors and neuroprotective mechanisms

Psychiatry and Clinical Psychopharmacology, 2021
There has been a resurgence of interest in recent years in monoamine oxidase inhibitors, primarily because of the demonstrated neuroprotective and/ or neurorescue properties of several of these drugs in a variety of toxic situations in vivo and in vitro.
Glen Baker, Dmitriy Matveychuk, Erin M. MacKenzie, Serdar Dursun, Darrell D. Mousseau   +4 more
doaj   +1 more source